RCS - Ondine Biomedical - Ondine Joins CAN Health Network

Ondine BiomedicalAnnouncement

12/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250512:nRSL1654Ia&default-theme=true

RNS Number : 1654I  Ondine Biomedical Inc.  12 May 2025

12(th) May 2025

ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")

Ondine Biomedical Joins CAN Health Network to Advance its Innovation in
Infection Prevention Across Canada

Membership provides strategic support, insights and connections as Ondine
works to scale its infection prevention technology.

Ondine Biomedical Inc. (LON: OBI) is pleased to announce its membership with
the CAN Health Network - a national initiative focused on accelerating the
adoption of Canadian technology within the health care system. Through this
membership, Ondine becomes part of a growing network of Canadian companies
that are working to address some of the sector's most complex challenges with
homegrown solutions.

As a member of the Network, Ondine will have access to strategic connections,
tailored support, and valuable market insights to help advance the adoption of
its innovative Steriwave(®) technology. This opportunity reflects Ondine's
ongoing commitment to improving health outcomes and contributing to a
stronger, more resilient Canadian health care system.

The CAN Health Network, a federally funded organization, is dedicated to
scaling Canadian healthcare innovation companies by connecting them with
healthcare operators nationwide. CAN Health facilitates the rapid
commercialization and widespread adoption of Canadian-made solutions, enabling
companies like Ondine to expand their reach and impact both domestically and
in global markets.

Carolyn Cross, CEO of Ondine Biomedical stated:

"Ondine Biomedical is proud to join the CAN Health Network. This membership
provides us with valuable opportunities to collaborate with Canada's foremost
healthcare innovators and further our goal of expanding access to Steriwave
and delivering enhanced patient outcomes across the country."

Ondine's Steriwave nasal photodisinfection offers a transformative approach to
infection prevention. This proprietary, light-activated antimicrobial rapidly
eliminates pathogens, including multidrug-resistant strains, without
contributing to the growing crisis of drug resistance.

Steriwave has demonstrated significant reductions in post-surgical infections
and impressive cost savings in both Canadian and UK hospitals. A 14-year study
led by Professor John Street, Director of the Integrated Ambulatory Spine
program at Vancouver General Hospital, showed a 66.5% reduction in spine
surgery infections, prompting the study authors to recommend nasal
photodisinfection as the standard of care for all spine surgeries. At Mid
Yorkshire NHS Teaching Trust in the UK, Steriwave achieved a 70% reduction in
the rate of knee and hip infections compared to a standard of care protocol
that included a topical nasal gel. Separately, a study by the York Health
Economics Consortium (YHEC) suggests that widespread adoption of Steriwave
could save UK hospitals up to £200 million annually by reducing surgical-site
infections.

Professor John Street has stated:

"In my opinion, there have been very few if any other initiatives that have
had such a profound and lasting impact on the health of British Columbians in
the past 10 years."

 

Enquiries:

 Ondine Biomedical Inc.                                      www.ondinebio.com
 Carolyn Cross, CEO                                          +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 RBC Capital Markets (Broker)
 Kathryn Deegan                                              +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                            +44 (0)77 1000 5910

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave(®). In the US, it has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

About CAN Health Network

The CAN Health Network is a federally funded, national organization
accelerating the adoption of Canadian innovation within the health care
system. The Network partners leading Canadian health care providers-known as
Edges-with homegrown technology companies to validate, procure, and scale
their solutions across Canada and beyond. By breaking down traditional
barriers to entry, CAN Health is helping Canadian companies grow while
strengthening the health care system. Learn more at canhealthnetwork.ca
(http://canhealthnetwork.ca) .

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPUQUAUPAGAG